dose conversion tirzepatide to semaglutide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are switching from tirzepatide to semaglutide

The weight-loss effect, initially a footnote in trial files, turned it into a household name

World J Surg Oncol

Detoxification and Skin Clarity The skin often reflects our internal health, and toxin accumulation can manifest as dullness, inflammation, and impaired barrier function

GLP-1RAs can improve the efficacy of protection against the adhesion of inflammatory cells to the endothelium

Experimental research has investigated its role in pigmentation, neuroendocrine signaling, and metabolic regulation, making it a valuable tool for exploring melanocortin receptor biology

Data availability statement References BMC Surg